Previous 10 |
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead It's that time again, as second-quarter earnings season kicks off in earnest with the usual early reports from banks - J...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Century Therapeutics (IPSC) said the underwriters of its Nasdaq IPO exercised their option in full to buy an additional 1,582,500 common stock at $20.00 per share for about $31.7MIn total the biotech sold 12,132,500 shares, raising about $242.7M in gross proceeds.Century's was -1.93...
PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of its initial public offering of 12,132,500 sh...
The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance International IPO Index was down 3.4% year-to-date, while the ACWX was up 10.4%. For f...
Devenorr/iStock via Getty Images Shares of Century Therapeutics (IPSC) closed up 14% to $22.83 on its first day of trading.The company priced its 10.6M-share IPO at $20/share.The biotech is developing human induced pluripotent stem cells ("iPSC") as an alternative to CAR-T therapies...
PHILADELPHIA, June 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the pricing of its initial public offering of 10,550,000 shares of its common ...
News, Short Squeeze, Breakout and More Instantly...
Century Therapeutics Inc. Company Name:
IPSC Stock Symbol:
NASDAQ Market:
Century Therapeutics Inc. Website:
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA m...
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD30...
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoim...